Gerald Cagle, an experienced pharmaceutical executive, has joined the board of directors of Eyevensys SAS, which is developing non-viral gene therapies for eye diseases. Dr Cagle is a former chief scientific officer at Alcon Laboratories Inc where he was responsible for the introduction of a range of new ophthalmic products. He holds 28 issued patents for both drugs and medical devices. Dr Cagle received a BS degree from Wayland Baptist University and MS and PhD degrees from the University of North Texas, US.
Eyevensys announced the appointment on 9 August 2018.
Copyright 2018 Evernow Publishing Ltd.